Biohaven Ltd. Earnings Per Share (Basic)
Biohaven Ltd. (BHVN) reported Earnings Per Share (Basic) of -$0.91 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- Biohaven Ltd. earnings per share, basic for the quarter ending 2026-06-30 was -$0.91.
- Biohaven Ltd. earnings per share, basic for the quarter ending 2026-03-31 was -$0.88.
- Biohaven Ltd. earnings per share, basic for the quarter ending 2025-12-31 was -$1.21.
- Biohaven Ltd. earnings per share, basic for the quarter ending 2025-09-30 was -$1.64.
- Biohaven Ltd. earnings per share, basic for fiscal 2025 was -$6.86.
- Biohaven Ltd. earnings per share, basic for fiscal 2024 was -$9.28.
- Biohaven Ltd. earnings per share, basic for fiscal 2023 was -$5.73.
- Biohaven Ltd. earnings per share, basic for fiscal 2022 was -$12.75.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.91 10-Q · filed 2026-08-10 | -$1.80 10-Q · filed 2026-08-10 | -$2.96 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$4.48 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2026-03-31 | -$0.88 10-Q · filed 2026-05-04 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$3.61 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$5.44 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-12-31 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$2.82 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$4.72 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$6.86 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.64 10-Q · filed 2025-11-10 | -$3.57 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$5.74 10-Q · filed 2025-11-10 | -$7.59 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-06-30 | -$1.94 10-Q · filed 2026-08-10 | -$4.11 10-Q · filed 2026-08-10 | -$5.96 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$7.67 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-03-31 | -$2.17 10-Q · filed 2026-05-04 | -$4.02 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$5.74 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$9.23 derived: net income ÷ weighted average shares · filed 2026-05-04 |
| 2024-12-31 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$3.55 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$7.06 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$9.28 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.70 10-Q · filed 2025-11-10 | -$5.27 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$7.50 10-Q · filed 2025-11-10 | -$9.36 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2024-06-30 | -$3.64 10-Q · filed 2025-08-11 | -$5.93 10-Q · filed 2025-08-11 | -$7.75 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$9.40 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2024-03-31 | -$2.20 10-Q · filed 2025-05-12 | -$4.01 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$5.57 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$6.94 derived: net income ÷ weighted average shares · filed 2026-03-02 |
| 2023-12-31 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$3.33 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$4.68 derived: net income ÷ weighted average shares · filed 2026-03-02 | -$5.73 10-K · filed 2026-03-02 |
| 2023-09-30 | -$1.50 10-Q · filed 2024-11-12 | -$2.83 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.86 10-Q · filed 2024-11-12 | -$7.00 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-06-30 | -$1.32 10-Q · filed 2024-08-09 | -$2.36 10-Q · filed 2024-08-09 | -$5.50 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$7.28 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-03-31 | -$1.03 10-Q · filed 2024-05-09 | -$4.21 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$6.06 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$10.47 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2022-12-31 | -$3.31 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$5.39 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$10.17 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$12.75 10-K · filed 2025-03-03 |
| 2022-09-30 | -$1.75 10-Q · filed 2023-11-14 | -$6.91 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$9.38 10-Q · filed 2023-11-14 | -$10.69 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-06-30 | -$5.16 10-Q · filed 2023-07-31 | -$7.63 10-Q · filed 2023-07-31 | -$8.94 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$10.32 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-03-31 | -$2.46 10-Q · filed 2023-05-12 | -$3.78 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$5.16 derived: net income ÷ weighted average shares · filed 2024-02-29 | |
| 2021-12-31 | -$1.32 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$2.70 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$5.43 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$1.38 10-Q · filed 2022-11-09 | -$4.11 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | -$3.01 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |